Unity Biotechnology

Unity Biotechnology was an American biotechnology company focused on senolytic medicines, a class of therapies intended to selectively remove senescent cells. Senescent cells are aged or damaged cells that stop dividing but can remain metabolically active and release inflammatory signals. Unity sought to use this area of biology to develop treatments for diseases associated with aging rather than to market a general-purpose anti-aging product. The company was founded in March 2009 under the name Forge, Inc. by Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou. Its scientific and commercial backing included prominent technology and life-sciences investors, including Jeff Bezos and PayPal co-founder Peter Thiel. In January 2015, the business changed its name to Unity BioTechnologies, later generally presented as Unity Biotechnology. The company was headquartered in South San Francisco, California. Unity became a publicly traded company on May 3, 2018, listing on the Nasdaq under the symbol UBX. Its initial public offering raised approximately $85 million and gave the company a reported market capitalization of about $700 million at the time. As a clinical-stage biotechnology company, Unity did not operate around an established portfolio of marketed medicines; its value depended principally on the progress of experimental candidates and the scientific validity of its senolytic platform. The company’s early lead program, UBX0101, was designed for osteoarthritis. The candidate was intended to address disease biology associated with senescent cells in the joint. In 2020, Unity reported disappointing results from a clinical trial in patients with moderate-to-severe painful osteoarthritis. The announcement caused the company’s shares to fall sharply, with the stock reportedly declining about 60% on August 17, 2020. The setback weakened the position of UBX0101 as the company’s leading program and contributed to a shift in emphasis toward ophthalmology. Unity’s later development focus included UBX1325, a senolytic candidate targeting Bcl-xL for age-related eye diseases, including diabetic macular edema. The company reported positive Phase 1 findings in July 2022. In April 2023, it announced Phase 2 results indicating that a single injection produced statistically significant and clinically meaningful visual improvement through 48 weeks. The company also identified UBX1967 as a preclinical ophthalmology program. These programs reflected Unity’s effort to apply senolytic biology to diseases in which localized treatment and measurable functional outcomes could support clinical development. Anirvan Ghosh became chief executive officer in 2020. Nathaniel David stepped down as president that year but remained on the board. Despite continued development activity around UBX1325, Unity ultimately ceased operations in 2025. Its history illustrates both the promise and the development risk of senolytic drug discovery: the company helped advance the clinical investigation of therapies targeting senescent cells, but its initial osteoarthritis program failed to establish efficacy and the business did not continue as an operating biotechnology company.

Unity Biotechnology originated in March 2009 as Forge, Inc., founded by Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou. The founders brought together expertise in biotechnology, aging biology, and cellular senescence. The company attracted backing associated with prominent technology and life-sciences investors, including Jeff Bezos and Peter Thiel, and pursued the idea that senescent cells could be therapeutically eliminated to treat diseases linked to aging. The company changed its name to Unity BioTechnologies in January 2015. The renaming aligned the business with its broader focus on unity between aging biology and drug development and established the identity under which it later became publicly known. Unity’s strategy was not to develop a cosmetic longevity product, but to create prescription medicines directed at specific age-related diseases. Its programs were based on senolytic mechanisms intended to remove or disable senescent cells that contribute to inflammation, tissue dysfunction, or impaired repair. Unity went public on Nasdaq on May 3, 2018, under the ticker UBX. The offering raised approximately $85 million and gave the business a reported market capitalization of about $700 million. As with many clinical-stage biotechnology companies, the public listing provided capital and visibility but also exposed the company to substantial valuation changes based on clinical readouts. The company’s principal early clinical program was UBX0101, an investigational senolytic drug developed for osteoarthritis. The candidate was evaluated in patients with moderate-to-severe painful osteoarthritis. In August 2020, Unity reported disappointing clinical results. The news was followed by a reported 60% fall in the company’s share price on August 17, 2020, demonstrating the importance of the program to investor expectations. That setback reduced the prospects of UBX0101 and encouraged a strategic concentration on other therapeutic areas. Leadership also changed in 2020. Anirvan Ghosh became chief executive officer, while co-founder Nathaniel David left the president role but continued as a board member. Under the subsequent development strategy, Unity placed greater emphasis on ophthalmology. Its leading later-stage program was UBX1325, a senolytic candidate directed at Bcl-xL and intended for age-related eye diseases, including diabetic macular edema. Unity reported positive Phase 1 results in July 2022. In April 2023, the company reported Phase 2 findings for UBX1325. According to the company’s account summarized in reference material, a single injection produced statistically significant and clinically meaningful improvement in vision through 48 weeks. Unity also described UBX1967 as a preclinical ophthalmology candidate. Both programs represented attempts to translate senolytic science into localized treatments with measurable clinical outcomes. Unity Biotechnology ultimately ceased operations in 2025. Its corporate history therefore ended before the company established a marketed medicine. The business remains notable for helping bring senolytic drug concepts into human clinical development, while also illustrating the scientific, regulatory, and financing risks involved in translating aging research into approved therapies.

• 2025

  Operations cease

  [1]Unity Biotechnologyen.wikipedia.org

  Unity Biotechnology ceased operations during 2025.

• 2023

  UBX1325 Phase 2 readout

  [1]Unity Biotechnologyen.wikipedia.org

  The company reported clinically meaningful visual improvement through 48 weeks after a single injection in a Phase 2 study.

• 2022

  Positive Phase 1 results for UBX1325

  [1]Unity Biotechnologyen.wikipedia.org

  Unity reported positive Phase 1 results for its Bcl-xL-targeting senolytic candidate in age-related eye disease.

• 2020

  Leadership transition and UBX0101 setback

  [1]Unity Biotechnologyen.wikipedia.org

  Anirvan Ghosh became CEO, and disappointing UBX0101 osteoarthritis results were reported later that year.

• 2018

  Nasdaq listing

  [1]Unity Biotechnologyen.wikipedia.org

  Unity Biotechnology completed its public offering on May 3, 2018, raising approximately $85 million under the ticker UBX.

• 2015

  Name changed to Unity BioTechnologies

  [1]Unity Biotechnologyen.wikipedia.org

  Forge, Inc. adopted the Unity BioTechnologies name in January 2015.

• 2009

  Company founded as Forge, Inc.

  [1]Unity Biotechnologyen.wikipedia.org

  Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou co-founded the biotechnology company in March 2009.

A clinical-stage biotechnology company focused on senolytic medicines for age-related diseases, with later emphasis on ophthalmic indications.

• Senolytic osteoarthritis drug candidate

  UBX0101

  UBX0101 was Unity Biotechnology’s early lead senolytic candidate for moderate-to-severe painful osteoarthritis. The program was based on the proposition that eliminating senescent cells in diseased joint tissue could reduce pathological signaling and improve symptoms or function. It entered clinical testing, but Unity reported disappointing results from a trial in 2020. The setback substantially reduced the program’s role in the company’s pipeline.

• Senolytic ophthalmology drug candidate

  UBX1325

  UBX1325 is a senolytic candidate designed to target Bcl-xL and remove senescent cells in age-related eye diseases. Unity studied it in ophthalmic indications including diabetic macular edema. The company reported positive Phase 1 results in July 2022 and later reported Phase 2 findings indicating statistically significant and clinically meaningful visual improvement through 48 weeks after a single injection. It was an investigational product and was not identified as an approved marketed medicine.

• Preclinical senolytic ophthalmology candidate

  UBX1967

  UBX1967 was described as a preclinical product candidate for ophthalmologic diseases. Like UBX1325, it belonged to Unity Biotechnology’s effort to apply senolytic mechanisms to localized eye conditions. The available reference material does not establish that the candidate advanced into human clinical trials or reached commercialization.

• 2023

  Report Phase 2 UBX1325 resultsOther

  Background

  Unity was evaluating whether UBX1325 could produce durable functional benefits in age-related ophthalmic disease.

  Action taken

  It reported Phase 2 results showing statistically significant and clinically meaningful visual improvement through 48 weeks after a single injection.

  Aftermath

  The results supported continued interest in UBX1325, but the available material does not establish regulatory approval or commercialization.

  Source

• 2022

  Advance UBX1325 into later clinical developmentProduct launch

  Background

  Following the failure of the osteoarthritis lead program, Unity focused on applying senolytic biology to age-related eye diseases.

  Action taken

  The company reported positive Phase 1 results for UBX1325 and continued its clinical development.

  Aftermath

  UBX1325 became the company’s principal reported clinical opportunity in ophthalmology.

  Source

• 2020

  Shift away from UBX0101 after osteoarthritis trialGeneration change

  Background

  UBX0101 was the company’s leading clinical program, but results in patients with moderate-to-severe painful osteoarthritis were disappointing.

  Action taken

  Unity reduced the strategic importance of the osteoarthritis program and placed greater emphasis on ophthalmology programs such as UBX1325.

  Aftermath

  The clinical setback was followed by a reported 60% decline in Unity shares and a reorientation of the pipeline.

  Reported share-price change after clinical results. Approximately 60% decline (August 17, 2020)

  Source

• 2018

  Initial public offeringOther

  Background

  Unity needed public-market capital to support development of experimental senolytic medicines.

  Action taken

  The company listed on Nasdaq on May 3, 2018, under UBX and raised approximately $85 million.

  Aftermath

  The listing made Unity a publicly traded clinical-stage biotechnology company and tied its valuation more closely to clinical progress.

  Initial public offering proceeds. $85 million raised (May 3, 2018)

  Source

• 2015

  Rebrand from Forge to Unity BioTechnologiesStrategy

  Background

  The company had been founded as Forge, Inc. and was developing a corporate identity around biotechnology and aging-related disease research.

  Action taken

  It changed its name to Unity BioTechnologies in January 2015.

  Aftermath

  The Unity identity became the company’s public brand through its later clinical development and Nasdaq listing.

  Source

1. 1Unity Biotechnologyen.wikipedia.org
2. 2Unity Biotechnology official websiteunitybiotechnology.com